Too many "exhausted" T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukemia (CLL) make it more challenging for chimeric antigen...

Bioengineers at the University of California San Diego have developed a cancer immunotherapy that pairs ultrasound with cancer-killing immune cells to destroy malignant tumors while sparing normal tissue. The...

Identifying markers that indicate severe COVID-19 disease trajectories could lead to early medical interventions and help reduce morbidity and mortality. In a new study posted to the bioRxiv* preprint...

As the coronavirus disease 2019 (COVID-19) pandemic began to spread rapidly across the world in 2020, among the first measures taken by panic-stricken governments was to seal their borders to travelers...

A new study, released on the bioRxiv* preprint server, shows that rapamycin, an immunosuppressive drug used in some cancers, and its analogs, may have an undesirable effect on viral entry into the host...

The coronavirus disease 2019 (COVID-19) pandemic continues to ravage worldwide, infecting over 118.15 million people. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the infection...

A new study from Boston Children’s Hospital and the Massachusetts Department of Health compared one of the latest rapid antigen tests for COVID-19—the Abbott BinaxNOW—with a highly accurate...

Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery...

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. HEXAXIM® DTPa-hepB-IPV-Hib Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA),...

First US COVID-19 vaccine recipient: ‘I stand by the science’ of the vaccine New York nurse Sandra Lindsay encourages people ‘not to be afraid’ of vaccination, says she is ‘feeling great’...